May 27th 2025
Explore the complex role of dopamine in schizophrenia, its impact on symptoms, and potential therapeutic advancements.
Southern California Psychiatry Conference
July 11-12, 2025
Register Now!
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia
View More
Southern Florida Psychiatry Conference
November 21-22, 2025
Register Now!
Real Psychiatry 2026
January 23-24, 2026
View More
Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?
View More
Optimizing Care for Patients With Tardive Dyskinesia
View More
Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia
View More
Highlights From the American College of Neuropsychopharmacology Annual Meeting
February 21st 2024Psychiatric Times highlighted takeaways from the 2023 American College of Neuropsychopharmacology Annual Meeting in our February issue. Don't miss out on these important conference clinical pearls!
Read More
Efficacy Studies of Semaglutide for Type 2 Diabetes Mellitus
February 13th 2024One meta-analysis that included data from 6 placebo-controlled and 7 active-controlled studies using subcutaneous semaglutide found that when compared with placebo, subcutaneous semaglutide 0.5 mg and 1 mg reduced hemoglobin A1c (HbA1c) by 1.01% and 1.38%, respectively.
Read More
BIAFAC and Posttraumatic Gut-Brain Axis Dysfunction
January 23rd 2024Brain injury associated fatigue and altered cognition has been associated with a subset of individuals with mild traumatic brain injuries who develop posttraumatic hypopituitarism, including altered gut microbiome and amino acid utilization.
Read More
HIV-Associated Neurocognitive Disorder: An Updated Pathophysiology
In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.
Read More
Is the Holiday Season Stroke Season?
December 4th 2023Research demonstrates a seasonal trend associated with stroke onset. More strokes occur between November and February than any other time period. Due to the holidays and other events, these months can be stressful and disrupt usual routines. Overeating, excessive alcohol intake, physical inactivity, and sleep deprivation frequently accompany the holidays and can increase risk for stroke. Clinicians can educate and provide strategies to effectively navigate the holiday season and potentially reduce risk for stroke.
Read More